Zhang Meiling, Hao Jingwei, Wu Yunjiao, Gao Ziyi, Wang Meng
Department of Respiratory Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
Front Oncol. 2024 Sep 26;14:1411548. doi: 10.3389/fonc.2024.1411548. eCollection 2024.
To assess the potential added value of the lung immune prognostic index (LIPI) in patients with small cell lung cancer (SCLC), treated with programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1) inhibitors, who lived in the Chinese alpine region.
120 SCLC patients treated with PD-L1/PD-1 inhibitors were divided into three LIPI groups, from July 2018 to April 2021. Cox regression models were used to evaluate the prognostic effect of three LIPI groups on overall survival (OS) and progression-free survival (PFS). Logistic regression analysis was conducted to explore the association between immune-related adverse events (irAEs) and the pretreatment of neutrophil-to-lymphocyte ratio (dNLR), lactate dehydrogenase (LDH), and LIPI.
The median OS was 4.5, 6.3, and 10.0 months () and the median PFS was 2.5, 4.3, and 5.3 months () for Poor, Intermediate, and Good LIPI, respectively. The disease control rate (DCR) was also higher in the Good LIPI group (). Moreover, multivariate analysis confirmed that worse LIPI was correlated with shorter OS and PFS. dNLR was associated with the onset of irAEs, not LIPI. Conclusion: The LIPI might be a promising predictive and prognostic biomarker in SCLC patients treated with PD-L1/PD-1 inhibitors in the Chinese Alpine region.
评估肺免疫预后指数（LIPI）对居住在中国高寒地区、接受程序性死亡配体1（PD-L1）/程序性死亡蛋白1（PD-1）抑制剂治疗的小细胞肺癌（SCLC）患者的潜在附加价值。
2018年7月至2021年4月，将120例接受PD-L1/PD-1抑制剂治疗的SCLC患者分为三个LIPI组。采用Cox回归模型评估三个LIPI组对总生存期（OS）和无进展生存期（PFS）的预后影响。进行Logistic回归分析，以探讨免疫相关不良事件（irAEs）与中性粒细胞与淋巴细胞比值（dNLR）、乳酸脱氢酶（LDH）及LIPI预处理之间的关联。
LIPI差、中、好组的中位OS分别为4.5、6.3和10.0个月（），中位PFS分别为2.5、4.3和5.3个月（）。LIPI好组的疾病控制率（DCR）也更高（）。此外，多因素分析证实LIPI越差与OS和PFS越短相关。dNLR与irAEs的发生有关，而与LIPI无关。结论：LIPI可能是中国高寒地区接受PD-L1/PD-1抑制剂治疗的SCLC患者有前景的预测和预后生物标志物。
